The antidepressant efficacy of zimelidine and maprotiline.
In a double-blind group comparison study of 39 patients with primary depressive illness zimelidine in a dose of 200 mg at night demonstrated the same order of antidepressant efficacy as maprotiline in a dose of 150 mg at night after either two or four weeks treatment measured by the amelioration or final score on the Hamilton Rating Scale (HRS) and on the Montgomery & Asberg Depression Rating Scale (MADRS). Both zimelidine and maprotiline demonstrated significant antidepressant activity at 2 weeks compared with 2 weeks prior treatment with placebo measured by amelioration on HRS (paired t 4.1 P less than 0.001, t 2.7 P less than 0.02) or MADRS (paired t 3.5 P less than 0.005, t 5.1 P less than 0.001). An item analysis of the MADRS showed significantly better sleep and appetite in the maprotiline-treated group compared with the zimelidine-treated group which is in accord with the pharmacology of the two compounds.